|Articles|September 12, 2019

Leprosy Outbreak in United States Only a 'Matter of Time,' One Physician Argues

Even though leprosy is not widespread in the United States, the current landscape in some cities, such as Los Angeles, is creating the perfect environment for so-called “ancient” diseases to flourish.

Certain populations in the United States are at risk for a resurgence of leprosy, or Hansen’s disease, according to a New York University physician who penned a public health warning in The Hill this week.

The US Centers for Disease Control and Prevention (CDC) reports there are only about 150 to 250 cases of leprosy reported in the United States in a given year, but between 2 and 3 million people are living with leprosy-related disabilities globally. It is more common in Central and South America, which see a combined average of 20,000 new cases per year.

Even though leprosy is not widespread in the United States, the current landscape in some cities, such as Los Angeles, is creating the perfect environment for so-called “ancient” diseases to flourish. Caused by the slow-growing bacteria Mycobacterium leprae, leprosy spreads more easily in close, unsanitary quarters.

Marc K. Siegel, MD, professor of medicine and medical director at Doctor Radio at NYU Langone Health, is sounding the alarm for his fellow physicians about the rise in diseases not seen since the Middle Ages, such as leprosy, and the conditions that contribute to the spread of these infections.

“…[I]t seems only a matter of time before leprosy could take hold among the homeless population in an area such as Los Angeles County, with close to 60,000 homeless people and 75% of those lacking even temporary shelter or adequate hygiene and medical treatment,” Siegel wrote in The Hill. “All of those factors make a perfect cauldron for a contagious disease that is transmitted by nasal droplets and respiratory secretions with close repeated contact.”

Leprosy is easily treatable with antibiotics when detected early; the problem is that early detection may be a hurdle for individuals experiencing homelessness, as they are not likely to be receiving regular medical care. And when left untreated, leprosy can lead to serious complications, including peripheral nerve damage, skin lesions, and even blindness.

“I am much more concerned about the permanent disabilities that come with leprosy—given that 2 million to 3 million people are affected worldwide—than I am with the associated stigma,” Siegel wrote. “Nevertheless, leprosy appearing among the homeless in LA is a sure recipe for instant public panic.”

In an interview with Contagion® earlier this year, Drew Pinsky, MD, delivered a similar warning to his fellow health care professionals, specifically calling out the unsanitary conditions on Los Angeles’ streets that are exacerbated by the large homeless population there.

“Now we have tuberculosis, measles, typhus…I started looking at what usually comes on the heels of typhus in this area, and that’s Yersinia (bubonic plague),” Pinsky, an internist and globally recognized addiction medicine specialist, said. “It has been documented on the squirrels, and it’s just a matter of time before it gets on the rats, then our pets, and then on us.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.